Share:
Masimo (NASDAQ:MASI) announced today the findings of a study published in the
Journal of Applied Physiology in which Dr. Marina García-de-Acilu and colleagues at the Vall d'Hebron University Hospital in Barcelona evaluated the utility of Masimo PVi
® as a noninvasive method of predicting preload responsiveness in patients treated with nasal high-flow (NHF) therapy. They found that PVi may identify preload responders and noted that PVi may therefore be used in the "day-to-day clinical decision-making process in critically ill patients treated with NHF, helping to provide adequate resuscitation volume."
1 More than 100 independent studies have demonstrated the utility of PVi as an indicator of fluid responsiveness.